Top Markets
#1 ONFA ONFA +218.69%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 NKN NKN +48.56%
#4 Noon Noon +41.33%
#5 Doge Strategy Doge Strategy +38.28%
#6 DeAgentAI DeAgentAI +30.80%
#7 StakeStone StakeStone +29.13%
#8 BLOCKv BLOCKv +28.38%
#9 OpenVPP OpenVPP +21.65%
#10 TronBank TronBank +16.89%
Coin of the day
ONFA ONFA
Settings
Language
ENGLISH
Currency
USD
Theme
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rank in Stocks #19705
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Share Price
$0.5275
Market Cap
$1.25M
Change (1 day)
-3.56%
Change (1 year)
-83.77%
Country
US
Trade Ensysce Biosciences, Inc. (ENSC)

Category

Healthcare
P/B ratio for Ensysce Biosciences, Inc. (ENSC)
P/B ratio as of March 2026 TTM: 0.98
According to Ensysce Biosciences, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.98. At the end of 2023 the company had a P/B ratio of -111.50.
P/B ratio history for Ensysce Biosciences, Inc. from 2017 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 0.98 -74.51%
2024 3.83 -103.44%
2023 -111.50 1,749.65%
2022 -6.03 -96.66%
2021 -180.44 -99.42%
2020 -30.98K -2,624.64%
2019 1.23K 14.10%
2018 1.08K 2.10%
2017 1.05K 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 479.58%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 554.05%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 151.52%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 347.09%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 161.28%
AU